Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Incyte (INCY) and Syndax (SNDX) announced that the FDA has approved Niktimvo in 9 mg and 22 mg vial sizes. The companies expect product to be ...

Companies on the 2023 Inc. 5000 are ranked according to percentage revenue growth from 2019 to 2022. To qualify, companies must have been founded and generating revenue by March 31, 2019.